GERN Stock Summary and Trading Ideas (Geron | NASDAQ:GERN)

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Geron trades on the NASDAQ stock market under the symbol GERN.

As of January 2, 2026, GERN stock price was flat at $1.32 with 5,340,292 million shares trading.

GERN has a beta of 1.46, meaning it tends to be more sensitive to market movements. GERN has a correlation of 0.15 to the broad based SPY ETF.

GERN has a market cap of $842.18 million. This is considered a Small Cap stock.

Last quarter Geron reported $47 million in Revenue and -$.03 earnings per share. This fell short of revenue expectation by $-6 million and exceeded earnings estimates by $.01.

In the last 3 years, GERN traded as high as $5.34 and as low as $1.04.

The top ETF exchange traded funds that GERN belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.

GERN has underperformed the market in the last year with a price return of -62.7% while the SPY ETF gained +17.8%. GERN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.6% and -5.7%, respectively, while the SPY returned +2.8% and +2.0%, respectively.

GERN support price is $1.27 and resistance is $1.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GERN shares will trade within this expected range on the day.